Список литературы

1. Руководство по кардиологии. Под ред. акад. Е.И. Чазова. В 4 томах. Москва, Издательский дом "Практика" 201.

2. Карпов Ю.А., Сорокин Е.В. "Стабильная ишемическая болезнь сердца: стратегия и тактика лечения". 2-е изд, перераб. и доп. - Москва, Медицинское информационное агентство, 2012. - 271.

3. Карпов Ю.А., Кухарчук В.В., Лякишев А.А., Лупанов В.П., Панченко Е.П., Комаров А.Л., Ежов М.В., Ширяев А.А., Самко А.Н., Соболева Г.Н., Сорокин Е.В. "Диагностика и лечение хронической ишемической болезни сердца (Практические рекомендации). Кардиологический вестник 2015; N 3: 3 - 33.

4. "Кардиология: национальное руководство" под ред. Е.В. Шляхто - 2-е изд., перераб. и доп. - М.: ГЭОТАР-Медиа, 2015. - 800 с.

5. Campeau L. Letter: "Grading of angina pectoris". Circulation 1976; 54: 522 - 523.

6. Montalescot G., Sechtem U., Achenbach S.et al. "2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable Coronary artery disease of European Society of Cardiology". Eur Heart J 2013; 34, 2949 - 3003.

7. Piepoli M.F., Hoes A.W., Stefan Agewall S., et al. "2016 European Guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical in Clinical Practice". European Heart Journal doi:10. 1093/eurheart/ehw106;

8. Кухарчук В.В., Коновалов Г.А., Сусеков А.В, и соавт "Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза". Атеросклероз и дислипидемии 2012; 2: 5 - 35;

9. Catapano A.L., Graham I., De Backer G., et al "2016 ESC/EAS Guidelines for the management of dyslipidaemias". Eur Heart J 2016; doi:10.1093/eurheartj/ehw272;

10. Лупанов В.П. "Современная стратегия, тактика ведения и прогноз пациентов со стабильной ишемической болезнью сердца". Кардиоваскулярная терапия и профилактика. 2016; 15(1): 77 - 83.

11. "Справочник по медикаментозному лечению сердечно-сосудистых заболеваний". Под ред. академика Е.И. Чазова. М., "Практика", 2015. - 320 с.

12. "Рациональная фармакотерапия сердечно-сосудистых заболеваний: руководство для практикующих врачей" под общ. ред. Е.И. Чазова, Ю.А. Карпова. - 2-е изд., испр. и доп. - М.: Литтерра, 2014. с 28 - 36.

13. Spertus JA, Salisbury AC, Jones PG, Conaway DG, Thompson RC. Predictors of quality-of-life benefit after percutaneous coronary intervention. Circulation 2004; 110(25): 3789 - 3794.

14. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, ESC/EACTS Guidelines 2613 Downloaded from https://academic.oup.com/eurheartj/article-abstract/35/37/2541/581070 by guest on 08 December 2017 Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabate M, Senior R, Taggart DP, van der Wall EE, Vrints CJ, Zamorano JL, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Valgimigli M, Claeys MJ, Donner-Banzhoff N, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Husted S, James SK, Kervinen K, Kristensen SD, Maggioni AP, Pries AR, Romeo F, Ryden L, Simoons ML, Steg PG, Timmis A, Yildirir A. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34(38): 2949 - 3003

15. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van't Veer M, Klauss V, Manoharan G, Engstrom T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF, Investigators FS. Fractional flow reserve vs. angiography for guiding percutaneous coronary intervention. N Engl J Med 2009; 360(3): 213 - 224.

16. Pijls NH, van Schaardenburgh P, Manoharan G, Boersma E, Bech JW, van't Veer M, Bar F, Hoorntje J, Koolen J, Wijns W, de Bruyne B. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol 2007; 49(21): 2105 - 2111.

17. Botman KJ, Pijls NH, Bech JW, Aarnoudse W, Peels K, van Straten B, Penn O, Michels HR, Bonnier H, Koolen JJ. Percutaneous coronary intervention or bypass surgery in multivessel disease? A tailored approach based on coronary pressure measurement. Catheter Cardiovasc Interv 2004; 63(2): 184 - 191.

18. Toth G, De Bruyne B, Casselman F, DeVroey F, PyxarasS, Di SerafinoL, VanPraet F, Van Mieghem C, Stockman B, Wijns W, Degrieck I, Barbato E. Fractional flow reserve-guided vs. angiography-guided coronary artery bypass graft surgery. Circulation 2013; 128(13): 1405 - 1411.

19. Denvir MA, Pell JP, Lee AJ, Rysdale J, Prescott RJ, Eteiba H, Walker A, Mankad P, Starkey IR. Variations in clinical decision-making between cardiologists and cardiac surgeons; a case for management by multidisciplinary teams? J Cardiothorac Surg 2006; 1:2

20. Windecker S, Kolh P, Alfonso F, Collet J-P, Cremer J, Falk V, Filippatos G, Hamm C, Head Stuart J, , Kappetein A.P, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann F-J, Richter D.J, Schauerte P, Sousa Uva M, Stefanini G.G, Taggart D.P, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart Journal 2014; 38, 2541 - 2619.

21. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas PE, Widimsky P, Alfieri O, Dunning J, Elia S, Kappetein P, Lockowandt U, Sarris G, Vouhe P, von Segesser L, Agewall S, Aladashvili A, Alexopoulos D, Antunes MJ, Atalar E, Brutel de la Riviere A, Doganov A, Eha J, Fajadet J, Ferreira R, Garot J, Halcox J, Hasin Y, Janssens S, Kervinen K, Laufer G, Legrand V, Nashef SA, Neumann FJ, Niemela K, Nihoyannopoulos P, Noc M, Piek JJ, Pirk J, Rozenman Y, Sabate M, Starc R, Thielmann M, Wheatley DJ, Windecker S, Zembala M. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010; 31(20): 2501 - 2555.

22. Deb S, Wijeysundera HC, Ko DT, Tsubota H, Hill S, Fremes SE. Coronary artery bypass graft surgery vs.percutaneous interventions in coronary revascularization: a systematic review. JAMA 2013; 310(19): 2086 - 2095.

23. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, Jagic N, Mobius-Winkler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engstrom T, Oldroyd KG, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Juni P, Fearon WF, Investigators FT. Fractional flow reserve-guided PCI vs. medical therapy in stable coronary disease. N Engl J Med 2012; 367(11): 991 - 1001.

24. Coronary angioplasty vs. medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet 1997; 350(9076): 461 - 468.

25. TIME Investigators. Trial of invasive vs. medical therapy in elderl ypatients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. Lancet 2001; 358(9286): 951 - 957.

26. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS, Group CTR. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356(15): 1503 - 1516.

27. Erne P, Schoenenberger AW, Burckhardt D, Zuber M, Kiowski W, Buser PT, Dubach P, Resink TJ, Pfisterer M. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. JAMA 2007; 297(18): 1985 - 1991.

28. Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360(24): 2503 - 2515.

29. Hueb W, Lopes N, Gersh BJ, Soares PR, Ribeiro EE, Pereira AC, Favarato D, Rocha AS, Hueb AC, Ramires JA. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2010; 122(10): 949 - 957.

30. Wijeysundera HC, Nallamothu BK, Krumholz HM, Tu JV, Ko DT. Meta-analysis: effects of percutaneous coronary intervention vs. medical therapy on angina relief. Ann Intern Med 2010; 152(6): 370 - 379.

31. Pursnani S, Korley F, Gopaul R, Kanade P, Chandra N, Shaw RE, Bangalore S. Percutaneous coronary intervention vs. optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials. Circ Cardiovasc Interv 2012; 5(4): 476 - 490.

32. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, Davis K, Killip T, Passamani E, Norris R et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344(8922): 563 - 570.

33. Bittl JA, He Y, Jacobs AK, Yancy CW, Normand SL. Bayesian methods affirm the use of percutaneous coronary intervention to improve survival in patients with unprotected left main coronary artery disease. Circulation 2013; 127(22): 2177 - 2185.

34. Dzavik V, Ghali WA, Norris C, Mitchell LB, Koshal A, Saunders LD, Galbraith PD, Hui W, Faris P, Knudtson ML. Long-term survival in 11,661 patients with multivessel coronary artery disease in the era of stenting: a report from the Alberta Provincial Project for Outcome AssessmentinCoronary HeartDisease(APPROACH) Investigators. Am Heart J 2001; 142(1): 119 - 126.

35. Smith PK, Califf RM, Tuttle RH, Shaw LK, Lee KL, Delong ER, Lilly RE, Sketch MH Jr., Peterson ED, Jones RH. Selection of surgical or percutaneous coronary intervention provides differential longevity benefit. Ann Thorac Surg 2006; 82(4): 1420 - 1428; discussion 1428 - 1429.

36. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie MC, O'Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH, Rouleau JL. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011; 364(17): 1607 - 1616.

37. Hannan EL, Samadashvili Z, Cozzens K, Walford G, Jacobs AK, Holmes DR Jr., Stamato NJ, Gold JP, Sharma S, Venditti FJ, Powell T, King SB 3rd. Comparative outcomes for patients who do and do not undergo percutaneous coronary intervention for stable coronary artery disease in New York. Circulation 2012; 125(15): 1870 - 1879.

38. Hannan EL, Wu C, Walford G, Culliford AT, Gold JP, Smith CR, Higgins RS, Carlson RE, Jones RH. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N Engl J Med 2008; 358(4): 331 - 341.

39. Caracciolo EA, Davis KB, Sopko G, Kaiser GC, Corley SD, Schaff H, Taylor HA, Chaitman BR. Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease. Long-term CASS experience. Circulation 1995; 91(9): 2335 - 2344.

40. Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, Sopko G, Ramires JA, Schneider D, Frye RL, Bypass Angioplasty Revascularization Investigation 2 Diabetes Study G. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation 2009; 120(25): 2529 - 2540.

41. Passamani E, Davis KB, Gillespie MJ, Killip T. A randomized trial ofcoronary artery bypass surgery. Survival of patients with a low ejection fraction. N Engl J Med 1985; 312(26): 1665 - 1671.

42. Jones RH, Kesler K, Phillips HR 3rd, Mark DB, Smith PK, Nelson CL, Newman MF, Reves JG, Anderson RW, Califf RM. Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease. J Thorac Cardiovasc Surg 1996; 111(5): 1013 - 1025.

43. Baker DW, Jones R, Hodges J, Massie BM, Konstam MA, Rose EA. Management of heart failure. III. The roleof revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. JAMA 1994; 272(19): 1528 - 1534.

44. Hachamovitch R, Rozanski A, Shaw LJ, Stone GW, Thomson LE, Friedman JD, Hayes SW, Cohen I, Germano G, Berman DS. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J 2011; 32(8): 1012 - 1024.

45. Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, Weintraub WS, O'Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller GV, Germano G, Gosselin G, Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK, Boden WE, Investigators C. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008; 117(10): 1283 - 1291.

46. Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003; 107(23): 2900 - 2907

47. Davies RF, Goldberg AD, Forman S, Pepine CJ, Knatterud GL, Geller N, Sopko G, Pratt C, Deanfield J, Conti CR. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy vs. revascularization. Circulation 1997; 95(8): 2037 - 2043.

48. Bangalore S, Pursnani S, Kumar S, Bagos PG. Percutaneous coronary intervention vs. optimal medical therapy for prevention of spontaneous myocardial infarction in subjects with stable ischemic heart disease. Circulation 2013; 127(7): 769 - 781.

49. Katritsis DG, Ioannidis JP. Percutaneous coronary intervention vs.conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation 2005; 111(22): 2906 - 2912.

50. Schomig A, Mehilli J, de Waha A, Seyfarth M, Pache J, Kastrati A. Ameta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease. J Am Coll Cardiol 2008; 52(11): 894 - 904.

51. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, KentDM. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network metaanalysis. Lancet 2009; 373(9667): 911 - 918.

52. Thomas S, Gokhale R, Boden WE, Devereaux PJ. A meta-analysis of randomized controlled trials comparing percutaneous coronary intervention with medical therapy in stable angina pectoris. Can J Cardiol 2013; 29(4): 472 - 482.

53. Jeremias A, Kaul S, Rosengart TK, Gruberg L, Brown DL. The impact of revascularization on mortality in patients with nonacute coronary artery disease. Am J Med 2009; 122(2): 152 - 161.

54. Kapoor JR, Gienger AL, Ardehali R, Varghese R, Perez MV, Sundaram V, McDonald KM, Owens DK, Hlatky MA, Bravata DM. Isolated disease of the proximal left anterior descending artery comparing the effectiveness of percutaneous coronary interventions and coronary artery bypass surgery. JACC Cardiovasc Interv 2008; 1(5): 483 - 491.

55. Aziz O, Rao C, Panesar SS, Jones C, Morris S, Darzi A, Athanasiou T. Meta-analysis of minimally invasive internal thoracic artery bypass vs. percutaneous revascularisation for isolated lesions of the left anterior descending artery. BMJ 2007; 334(7594): 617.

56. Blazek S, Holzhey D, Jungert C, Borger MA, Fuernau G, Desch S, Eitel I, de Waha S, Lurz P, Schuler G, Mohr FW, Thiele H. Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: 10-year follow-up of a randomized trial. JACC Cardiovasc Interv 2013; 6(1): 20 - 26.

57. Thiele H, Neumann-Schniedewind P, Jacobs S, Boudriot E, Walther T, Mohr FW, Schuler G, Falk V. Randomized comparison of minimally invasive direct coronary artery bypass surgery vs. sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis. J Am Coll Cardiol 2009; 53(25): 2324 - 2331.

58. Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stahle E, Colombo A, Mack MJ, Holmes DR Jr., Morel MA, Van Dyck N, Houle VM, Dawkins KD, Serruys PW. Coronary artery bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013; 381(9867): 629 - 638.

59. Capodanno D, Stone GW, Morice MC, Bass TA, Tamburino C. Percutaneous coronary intervention vs. coronary artery bypass graft surgery in left main coronary artery disease: a meta-analysis of randomized clinical data. J Am Coll Cardiol 2011; 58(14): 1426 - 1432.

60. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Stahle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW. Percutaneous coronary intervention vs. coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360(10): 961 - 972.

61. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S 3rd, Bertrand M, Fuster V, Investigators FT. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012; 367(25): 2375 - 2384.

62. Head SJ, Davierwala PM, Serruys PW, Redwood SR, Colombo A, Mack MJ, Morice MC, Holmes DR, Feldman TE, Staehle E, Underwood P, Dawkins KD, Kappetein AP, Mohr FW. Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year followup of the SYNTAX trial. Eur Heart J. Published online 21 May 2014; doi: 10.1093/eurheartj/ehu213.

63. Stefanini GG, Byrne RA, Windecker S. State of the art: coronary artery stent - past, present and future. 2017: 706 - 716.

64. Kirtane AJ, Gupta A, Iyengar S, и др. Safety and Efficacy of Drug Eluting and Bare Metal Stents: Comprehensive Meta-Analysis of Randomized Trials and Observational Studies. Circulation. 2009; 119(25): 3198 - 3206.

65. Sarno G, Lagerqvist B, , и др. Lower risk of stent thrombosis and restenosis with unrestricted use of "new-generation" drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J. 2012; 33(5): 606 - 613. doi:10.1093/eurheartj/ehr479.

66. Stone GW, Rizvi A, Newman W, и др. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010; 362(18): 1663 - 1674. doi:10.1056/NEJMoa0910496.

67. Kedhi E, Joesoef KS, McFadden E, и др. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010; 375(9710): 201 - 209. doi:10.1016/S0140-6736(09) 62127-9.

68. Stefanini GG, Byrne RA, Serruys PW, и др. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J. 2012; 33(10): 1214 - 1222. doi:10.1093/eurheartj/ehs086.

69. E. Braunwald, D.L. Mann, D.P. Zipes, P. Libby, R.O. Bonow. Braunwald's Heart Disease: A Textbook Of Cardiovascular Medicine, Tenth Edition. Elsevier Saunders, 2015. p. 1241.

70. Toyota T, Morimoto T, Shiomi H, Yoshikawa Y, Yaku H, Yamashita Y, Kimura T. JACC Cardiovasc Interv. 2017 Jan 9; 10(1): 27 - 37.

71. Lipinski MJ, Escarcega RO, Baker NC, Benn HA, Gaglia MA Jr, Torguson R, Waksman R. JACC Cardiovasc Interv. 2016 Jan 11; 9(1): 1224.